Monospecific anti-B antibody and ABO blood group ab 49 € als Taschenbuch: Isolation and partial Characterization of Monospecific anti-B antibody and Cloning of Human ABO blood group gene. Aus dem Bereich: Bücher, Wissenschaft, Medizin,
The large volume requirements for high quality ABO and Rh(D) typing reagents can now be supplied by selected monoclonal antibodies using hybridoma technology. In this book two efficient methods for the industrial production of Monoclonal antibody is described. This products have major advantages in lot-to-lot consistency in both potency and specificity, and have minimal processing requirements no defibrination, delipidisation or absorption of unwanted anibodies.
Monospecific antibodies are antibodies raised against a specific antigen used extensively in basic biomedical research, diagnosis and treatment of a disease such as infections and cancer. In the present study monospecific antibodies were produced against antigen B of the ABO blood group system to be used as a diagnostic marker for blood group B typing. The work was performed in the laboratory of Vaccinology and Molecular Immunology at the Center of Virology and Immunology, National University of Science and Technology. The research was supervised by Dr. Muhammad Ali A Shah and Co-supervised by Dr. Kashif Asghar, with the help of Dr. Taimoor Ashiq who was the internal member of the principal author, Bilal Zulfiqar. The work was fully guided by Dr. Isthtiaq Qadri, the Prinicipal of the Center.
Merozoite surface protein MSP2 is avaccine candidate antigen of Plasmodium falciparum that is polymorphic in natural populations. In this study we aimed to investigate whether malaria infection in associated with anti-malaria specific IgG, using recombinant proteins derived from the two major allelic types of MSP2 and ABO blood group. The conclusion is the Higher anti-malarial IgG1, IgG3, IgG2 and lower levels of IgG4 were associated with reduced risk of malaria infection. IgG2 is activator of the classical complement pathway, Fc RIIa H131 is essential for handling IgG2 immune complexes. These data suggest that an MSP2 based vaccine should be designed to induce high level antibody responses against the different MSP2 types present globally in P. falciparum populations and that MSP2 could be combined with other P. falciparum antigens to form a multi-component malaria vaccine.
This book introduces the clinical application of ABO-incompatible transplantation. In the first part, it starts with the history, blood group antigen, antibody associated with ABO blood type, pathophysiology and pathology and related knowledge. In the second part, it covers clinical experience sharing of ABO-incompatible of heart, liver, lung and kidney transplantation. It provides a systematic methodologies and protocols.
As recent advances in immunosuppression and apheresis techniques have opened new avenues for the management of humoral immunity, interest in ABO-incompatible kidney transplantation has been renewed. Moreover, new screening techniques - such as the single antigen bead assay - allow for the detection and definition of very low levels of alloantibody, which has had a positive impact on the treatment possibilities in highly sensitized adult patients with end-stage renal disease. But despite these advances, a theoretical rationale is still missing for both the decision to transplant a sensitized patient and the classification of the transplant as low, medium or high risk. There is also no uniform approach with regard to pre-transplant desensitization protocols, and it is unclear whether particular post-transplant immunosuppression will be required and what would be the best combination treatment. Last but not least, the frequency and actual clinical impact of alloantibodies developed after transplantation on short- and long-term graft survival need to be ascertained. Aimed especially at the clinician, this publication presents recent insights in the characterization and pathogenetic role of humoral immunity in chronic allograft injury and investigates the perspectives for novel immunosuppressive therapies to control antibody production after transplantation.
This book presents state of the art knowledge on all aspects of kidney transplantation in recipients in whom desensitization strategies are necessary in order to overcome immunologic barriers such as anti-human leukocyte antigen (HLA) donor-specific antibody and ABO blood group incompatibility. Readers will find detailed, up-to-date information on the various immunomodulating therapies that may be employed in these circumstances and the outcomes that may be expected. Full guidance is provided on preoperative evaluation and management and post-transplantation care. In addition, the pathology of antibody-mediated rejection and acute cellular rejection in this context is discussed.For most patients with end-stage renal disease, kidney transplantation offers significant benefits compared with dialysis, but especially sensitization to HLAs remains a major clinical obstacle to success. Kidney Transplantation in Sensitized Patients will assist in achieving optimal results in individual patients. It will be an important resource for everyone involved in the care of kidney transplant recipients.
The large volume requirements for high quality ABO and Rh(D) typing reagents can now be supplied by selected monoclonal antibodies using hybridoma technology. In this book two efficient methods for the industrial production of Monoclonal antibody is described. This products have major advantages in lot-to-lot consistency in both potency and specificity, and have minimal processing requirements-no defibrination, delipidisation or absorption of unwanted anibodies.